Prevention of breast cancer: the case for studying inhibition of IGF-1 actions

被引:3
|
作者
Smith, J. [1 ]
Axelrod, D. [2 ]
Singh, B. [3 ]
Kleinberg, D. [1 ]
机构
[1] NYU, Inst Canc, Dept Med, New York, NY USA
[2] NYU, Inst Canc, Dept Surg, New York, NY USA
[3] NYU, Inst Canc, Dept Pathol, New York, NY USA
关键词
breast cancer; IGF-1; mammary development; pasireotide; raloxifene; SOM230; tamoxifen; FACTOR-I ACTION; GROWTH; CHEMOPREVENTION; TAMOXIFEN; RISK;
D O I
10.1093/annonc/mdq666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Measures to prevent breast cancer are receiving particular attention by women at high risk from either clinico-pathologic findings or genetic susceptibility. Life-style and nutritional interventions have been difficult to quantify, but merit further study. Chemoprevention with tamoxifen and subsequently with the related raloxifene demonstrates some efficacy, but may be not be applicable to premenopausal women (with regard to raloxifene), or have low acceptance (with regard to tamoxifen). Based on the importance of the insulin-like growth factor-1 pathway in mammary gland development, and the availability of a potent inhibitor, pilot studies are ongoing to evaluate such an inhibitor in women with demonstrable high risk to develop breast cancer. Short-term interventions with the inhibitor have been completed, and subsequent interventions are planned.
引用
收藏
页码:i50 / i52
页数:3
相关论文
共 50 条
  • [31] Nutrition, GH/IGF-1 signaling, and cancer
    Fanti, Maura
    Longo, Valter D.
    ENDOCRINE-RELATED CANCER, 2024, 31 (11)
  • [32] Actions of alcohol and IGF-1 during female pubertal development.
    Dees, W. L.
    Srivastava, V. K.
    Pine, M.
    Hiney, J. K.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (06) : 294A - 294A
  • [33] Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    Wolf, I.
    Levanon-Cohen, S.
    Bose, S.
    Ligumsky, H.
    Sredni, B.
    Kanety, H.
    Kuro-o, M.
    Karlan, B.
    Kaufman, B.
    Koeffler, H. P.
    Rubinek, T.
    ONCOGENE, 2008, 27 (56) : 7094 - 7105
  • [34] IGF-1 PREDICTS IMPROVED MEMORY FUNCTION IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY
    Janelsins, Michelle C.
    Yao, Song
    Mustian, Karen M.
    Peppone, Luke J.
    Heckler, Charles E.
    Ambrosone, Christine B.
    Morrow, Gary R.
    ANNALS OF BEHAVIORAL MEDICINE, 2014, 47 : S236 - S236
  • [35] Pubertal Growth, IGF-1, and Windows of Susceptibility: Puberty and Future Breast Cancer Risk
    Biro, Frank M.
    Huang, Bin
    Wasserman, Halley
    Gordon, Catherine M.
    Pinney, Susan M.
    JOURNAL OF ADOLESCENT HEALTH, 2021, 68 (03) : 517 - 522
  • [36] Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    I Wolf
    S Levanon-Cohen
    S Bose
    H Ligumsky
    B Sredni
    H Kanety
    M Kuro-o
    B Karlan
    B Kaufman
    H P Koeffler
    T Rubinek
    Oncogene, 2008, 27 : 7094 - 7105
  • [37] Prognostic value of IGF-1 and IGFBP-3 blood levels in breast cancer
    Hartog, H.
    Boezen, H. M.
    de Jong, M. M.
    Schaapveld, M.
    Wesseling, J.
    van der Graaf, W. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Obesity induces breast cancer cell invasion through stromal secretion of IGF-1
    Hillers, Lauren
    D'Amato, Joseph
    Chamberlin, Tamara
    Paderta, Gretchen
    Arendt, Lisa
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Resistance Training And Protein Supplementation On IGF-1, Adiponectin And CRP In Breast Cancer Survivors
    Madzima, Takudzwa A.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2016, 48 (05): : 397 - 397
  • [40] IGF-1 and IGF-2 serum concentrations in patients with benign and malignant breast cancer: free IGF-2 Is correlated with breast tumor size
    Singer, CF
    Mogg, M
    Koestler, W
    Marton, E
    Pacher, M
    Kubista, E
    Schreiber, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S54 - S54